Drug Profile
Lacutamab - Innate Pharma/University of Genoa
Alternative Names: Anti-KIR3DL2 antibody; Anti-KIR3DL2 cytotoxic mAb; IPH 41; IPH4102Latest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator University of Genoa
- Developer Innate Pharma; Lymphoma Academic Research Organisation
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; KIR3DL2 receptor antagonists; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cutaneous T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome
Most Recent Events
- 19 Jan 2024 Efficacy and safety data from a phase I trial in Peripheral T-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 04 Jan 2024 US FDA lifts the partial clinical hold placed on the phase II TELLOMAK trial for Cutaneous T-cell lymphoma
- 10 Dec 2023 Adverse events and efficacy data from the phase-II TELLOMAK trial in Sezary Syndrome presented at the American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)